Navigation Links
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
Date:3/13/2008

Data Suggest Majority of Pompe Patients May Be Amenable to Chaperone

Therapy

CRANBURY, N.J., March 13 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present positive results from an ex vivo response study and three Phase 1 studies of AT2220 (1-deoxynojirimycin HCl), Amicus' compound in development for the treatment of Pompe disease, at the American College of Medical Genetics (ACMG) Annual Meeting from March 12-16 in Phoenix, AZ. The results of the ex vivo response study along with the previously reported results of the Phase 1 studies support moving into Phase 2 trials in the first half of 2008.

Ex Vivo Response Study data

Interim data will be presented from an ex vivo response study designed to test the effect of AT2220 on various Pompe mutations. Blood and skin samples were collected from 30 Pompe patients (26 adults, 3 juveniles and 1 infant) with a variety of different mutations in acid alpha-glucosidase (GAA), the target enzyme in Pompe disease. Cells derived from these samples were then tested to determine whether treatment with AT2220 caused an increase in the level of GAA. Of the 26 patients with available data, 24 had cells that showed a dose responsive increase in GAA levels, including 22 patients who had at least 1 copy of the common splice site mutation IVS1-13T>G. It has been reported that more than 80% of Caucasian adult Pompe patients have at least 1 copy of this common splicing mutation.

Phase 1 AT2220 data

A total of 72 healthy volunteers were treated in three double-blind, placebo-controlled, dose escalation Phase 1 studies designed to evaluate the safety, tolerability and pharmacokinetics of AT2220. Across all three studies, AT2220 was shown to be generally safe and well tolerated at all doses. The
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
2. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INC. (NYSE: RMD ) today announced that it ... on Thursday, January 22, 2015, after the New York Stock ... be issued after 1:00 p.m. US Pacific Time and the ... future outlook. The earnings call is scheduled to ... webcast of the call can be accessed on ResMed,s Investor ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... Corporation (NASDAQ: VOLC ), a global leader in ... that they have entered into a definitive merger agreement. Pursuant ... acquire all of the issued and outstanding shares of Volcano ... price of USD 1 billion (approx. EUR 800 million), to ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... , , MEMPHIS, Tenn. , Jan. 20 ... SN) Orthopaedics business is making available this week more than $2 ... in the treatment of survivors of last week,s earthquake in Haiti ... range of orthopedic surgical resources used to treat bone fractures. , ...
... Fla. , Jan. 20 Roper Industries, ... for the fourth quarter of 2009, ended December 31, 2009 , ... 2010 .  A conference call to discuss these results has been scheduled ... .  The call can be accessed via webcast or by dialing +1 ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments 2Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments 3
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of the ... (HRV), heart coherence and the physiology of emotions, ... algorithms to chipset manufacturers and consumer electronics companies. ... offer its HRV solutions, tap into its HRV ... normative HRV databases and algorithms for developing consumer ...
(Date:12/17/2014)... No matter how far modern medicine ... the head louse parasite—a common childhood malady and a ... between six and twelve million individuals will suffer an ... treatment company comes to the rescue, providing an all-natural ... its track record of customer service, and effectiveness in ...
(Date:12/17/2014)... 2014 (HealthDay News) -- As gas prices rose in ... new study suggests. In times of gas increases, ... riders are inexperienced, the researchers explained. They examined ... has the highest number of motorcycle registrations in the ... deaths. The analysis revealed a strong association between ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Poor students get more ... a new study finds. But, the opposite is true ... having fruits and vegetables at school may give a healthy ... But, no matter what the family income level, students all ... the study found. The study was published recently in ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2
... , , THURSDAY, Nov. 1 (HealthDay News) -- Heart disease ... for an individual,s brothers or sisters, too, U.S. researchers ... among brothers, the Johns Hopkins University team found. For ... chest pain from blocked arteries, the other is 20 ...
... SACRAMENTO, Calif., Nov. 1 Always Best Care ... California,areas. America,s premier In-Home Care, Assisted Living Placement ... seniors in Granada,Hills/Sherman Oaks can now rely on ... over a decade, a caring relationship has been ...
... Addition to Postal Service Social Awareness Stamp,Series, WASHINGTON, ... next year to help raise awareness about Alzheimer,s disease,as ... John,Potter announced today, on the first day of both ... "With the Alzheimer,s Awareness commemorative stamp, we,ll ask,Americans ...
... the current issue of Clinical Pharmacology & Therapeutics, ... Bioethics and Johns Hopkins Berman Institute of Bioethics ... vaccine debate, and its effects on ethical and ... was a major achievement for cervical cancer prevention ...
... program,s launch, study found , , THURSDAY, Nov. 1 (HealthDay ... Part D prescription drug benefit increased the number of ... $32 billion to Medicare, a new study concludes. , ... Health Affairs , the study authors noted that many ...
... a statement,from ADA President Mark J. Feldman:, "The ... Camp (R-MI) for introducing legislation that will help bring ... tribal areas,where too many people lack sufficient access to ... "The Native American Full Access to Dental Care ...
Cached Medicine News:Health News:Siblings Often Share Heart Risks 2Health News:Siblings Often Share Heart Risks 3Health News:Announcing Always Best Care Senior Services Expansion Into the Granada Hills/Sherman Oaks, California Areas 2Health News:Alzheimer's Disease to be Highlighted on Stamp Next Year 2Health News:A missed shot: The failure of HPV vaccination state requirements 2Health News:A missed shot: The failure of HPV vaccination state requirements 3Health News:Medicare Drug Plan Cost $32 Billion in 2006 2Health News:Medicare Drug Plan Cost $32 Billion in 2006 3Health News:Statement by ADA President Mark J. Feldman on the Native American Full Access to Dental Care Act 2
...
Bimod, acetabular cup "Xl" UHMWHDPE....
Metal on metal hip acetabular cups available for both cemented and cementless applications, the Biomet Merck metal on metal articulation hip system (M2aTM) combines proven materials with the latest i...
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Medicine Products: